[Antiviral effects of dual-target antisense LNA by cationic liposomes in transgenic mice]
Yibin Deng1, Legen Nong, Yesheng Wei
1Center for Medical Laboratory Science, the Affiliatied Hospital of Youjiang Medical College for Nationalities, Baise 533000, China. dyb0776@sina.com
Abstract:
This paper is aimed to investigate the inhibitory effects of hepatitis B virus (HBV) preC and C genes-specific antisense locked nucleic acid (LNA) on HBV replication and expression in transgenic mice. The antisense LNA, which was complementary to the preC and C gene region of HBV, was designed, synthesized, and injected into transgenic mice via the tail vein. Serum HBV DNA was tested with real-time PCR, and Serum HBsAg was tested with time-resolved fluorescence immune assay (TRFIA). Then the expression of HBcAg in the liver was detected with immuneohistochemistry. Serum ALB, ALT, BUN and CRea were measured with an antomatic biochemicall analyzer. It was found that 5 days after LNA injection, serum HBV DNA levels in the dual-target group were reduced by 53.72%, and serum HBsAg levels were decreased by 71.57%. These values were significantly higher than those in the control groups (P<0.05) and the expression levels of HBcAg in the liver were significantly lower than those in the control groups (P<0.05). The result also showed that there were no significant differences discovered in serum ALB, ALT, BUN and CR between the experiment groups and the control groups. The present study provides that antisense LNA targeting to both preC and C genes has shown strong inhibition on HBV replication and expression in transgenic mice, and stronger than target at single gene site.
Insights
Antisense locked nucleic acid (LNA) targeting hepatitis B virus (HBV) preC and C genes significantly inhibits HBV replication and expression in mice. Dual-target LNA demonstrated superior efficacy compared to single-target LNA.
Area of Science:
- Hepatology
- Molecular Virology
- Antisense Oligonucleotide Therapeutics
Context:
- Hepatitis B virus (HBV) infection remains a major global health concern.
- Current treatments for chronic HBV infection have limitations.
- Targeting viral gene expression offers a potential therapeutic strategy.
Purpose:
- To investigate the inhibitory effects of dual-target antisense locked nucleic acid (LNA) against hepatitis B virus (HBV) preC and C genes.
- To evaluate the efficacy of this LNA in reducing HBV replication and expression in a transgenic mouse model.
- To compare the effectiveness of dual-target LNA with single-target LNA.
Summary:
- Antisense LNA targeting both HBV preC and C genes was designed, synthesized, and administered to transgenic mice.
- Significant reductions in serum HBV DNA (53.72%) and HBsAg (71.57%) were observed post-injection.
- Liver HBcAg expression was also significantly decreased, with no adverse effects on liver and kidney function markers.
Impact:
- Demonstrates potent inhibition of HBV replication and gene expression by dual-target antisense LNA in vivo.
- Suggests that dual-target LNA is more effective than single-target LNA for HBV inhibition.
- Highlights the therapeutic potential of LNA technology for treating chronic hepatitis B.


